Jakavi Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Ruxolitinib phosphate

Indications/Uses

Disease-related splenomegaly &/or symptoms in adult patients w/ myelofibrosis (MF) including primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF. Adult patients w/ polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Patients ≥12 yr w/ acute or chronic graft versus host disease (GvHD) who have inadequate response to corticosteroids.

Dosage/Direction for Use

MF Platelet count >200,000/mm³ 20 mg bd, 100,000-200,000/mm³ 15 mg bd, 75,000 to <100,000/m² 10 mg bd, 50,000 to <750,000/mm³ 5 mg bd. Severe renal impairment (CrCl <30 mL/min) Reduce dose by approx 50%. Patient on dialysis Initially single dose of 15 mg or 20 mg based on platelet count w/ subsequent single doses only after each dialysis session. PV 10 mg bd. Severe renal impairment (CrCl <30 mL/min) 5 mg bd. Patient w/ ESRD on hemodialysis Single dose of 10 mg or 2 doses of 5 mg given 12 hr apart to be administered post-dialysis & only on hemodialysis day. MF & PV Hepatic impairment Reduce dose by approx 50% bd. Acute GvHD 5-10 mg bd. Chronic GvHD 10 mg bd. Acute & chronic GvHD Severe renal impairment 5 mg bd. ESRD on dialysis 10 mg once after dialysis.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EJ01 - ruxolitinib ; Belongs to the class of Janus-associated kinase (JAK) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Jakavi tab 10 mg

Packing/Price

1's

Form

Jakavi tab 15 mg

Packing/Price

1's

Form

Jakavi tab 20 mg

Packing/Price

1's

Form

Jakavi tab 5 mg

Packing/Price

1's

Jakavi

ruxolitinib

Manufacturer:

Novartis Pharma Stein AG